Home | RheumNow

Recent News

Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target
Save

Sheila Reyes, MD

Nov 03, 2026

A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.

Read Article

Exagen studies 192 established RA pts (383 controls) for Abs: CCP2, RF IgA, RF IgM, PAD4 (IgA, IgG). RA signif assoc w/ CCP2+ (OR 110), RF (>7), PAD4 (3.5-5.9). In CCP neg - only PAD4 IgG (2.87) & RF (2.2) assoc w/ RA, w/ only small Dx gain (ΔAUC 0.02–0.04). https://t.co/isf7aMf24O

Spanish Nationwide registry study of 5120 hospitalised #GCA pts (2016-2024) found that 54 (1.1%) Dx / aortic aneurysm (AA) & 41 (0.8%) developed AA on F/U (AAf group). Median time to AA Dx 2.7 yrs. AA Risk was higher in males (RRR 2.42) & smoking w/ GCA (RRR 3.23) https://t.co/eZVGKbOfQt

THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf

AxSpA SIG Baraliakos - CD74 abs in SpA - what other abs need exploration? @RheumNow #APLAR2026 https://t.co/rftgYQH4mX

Key messages from Dr. Vaidya’s talk: - Assocn’s of hyperuricemia or gout with MetS shows a bidirectional trend - Causality: MetS as an upstream driver for gout devt Going beyond jt dse & ULT. What addt’l assessments do you do for your gout pts? @RheumNow #APLAR2026 https://t.co/M6XVoRQ5rz

Perspective from dentists on SjD dry mouth: muscarinic agonists (pilocarpine, cevimeline) help, but side effects limit use. Two ways to improve it: split pilocarpine dosing (2.5 mg four times daily) and a cevimeline mouth rinse in 6 or more divided doses. #APLAR26 @RheumNow https://t.co/phiLD0qaoR

@RheumNow Do the two fixes work? Split pilocarpine (n=20 SjD, 4 weeks): sweating severity 3.7 to 1.7 (p<0.001), oral dryness VAS 61.0 to 43.6 (p=0.011). Cevimeline rinse (n=12 SjD): unstimulated salivary flow higher than juice control at 1 and 2 h. Small studies. #APLAR26 @RheumNow https://t.co/LEDHFGwh8Q

Lupus/LN should not be a sole indication for a C-section C-section should be reserved for obstetric indications. Adapt a multidisciplinary approach. @RheumNow #APLAR2026 https://t.co/vrXeNP9xLI

https://x.com/RHEUMarampa/status/2116726182029009040/photo/1

There is physiologic proteinuria in pregnancy so be careful before attributing a rise of levels to active LN LN flare vs. pre-eclampsia: both can present w/ HTN, edema, low plts and inc crea. > monitor C3 changes during each trimester of pregnancy @RheumNow #APLAR2026 https://t.co/Pp6GGeLPC6

Monitoring ILD in SjD: reassess risk at every visit. High risk with disease duration under 1 year: PFTs every 3-6 months, HRCT at 1 year. Lung biopsy has no role in diagnosis, except for atypical HRCT features or to exclude malignancy. #APLAR26 @RheumNow https://t.co/tFPNi0S8y8

The growing unmet needs of repro health in the @APLAR_org region lead to dev’t of new consensus statements Provides a practical guide for rheums focusing on key areas like preconception, meds safety in pregnancy & men w/AIRDs planning to become fathers etc @RheumNow #APLAR2026 https://t.co/xCKmpcD4ma

Same molecule, different route, different persistence: golimumab IV persisted 4.44 yrs vs 2.07 for SC in biologic-naive RA (n=9,464, Korean claims). Is it the route, or differenntial out of pocket cost, or supervised dosing and better adherence? P#240 #APLAR26 @RheumNow

Older adults with RA on JAKi: filgotinib may carry a lower zoster risk than others. Is it JAK1 selectivity? UPA (available in the US) is also selective. Dose, zoster vaccination status and a mixed comparator group may matter. Day 3 Abst Session 7 #APLAR26 @RheumNow https://t.co/5ri4shAHnV

This interesting study by @doktora_ging et al describes the notable differences in skin lesions bet Filipino vs caucasian. Fil skin: darker lesions, marked contrast bet hypo/hyperpigmentation, more gray & black psor plaques Practical & informative. @RheumNow #APLAR2026 https://t.co/A1dyFRNkwV

Guidelines similar for GC use in pregnancy. For @APLAR_org , non-fluorinated gcs are recommended and much lower doses of prednisone <5mg/day as the target with IV MP preferred for severe disease. Universal recos to monitor BP, glucose and steroid-related SEs @RheumNow #APLAR https://t.co/FrQEsbLbOk

https://x.com/RHEUMarampa/status/2116922932379435196/photo/1

article

FDA Approves Tildrakizumab for Psoriatic Arthritis

Jack Cush, MD Nov 02, 2026

Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor approved for use in PsA.

Does IVIG have a Role in Scleroderma? A recent systemic review and meta-analysis by Jozelio Freire de Carvalho and colleagues analyzed the available literature on this therapy. This study, published in Frontiers in Immunology in October 2026, evaluated the available evidence https://t.co/a8J2UT2I7Y

Beyond Chondrocalcinosis - What’s New in CPPD Disease An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and https://t.co/HmDgB9nNbm

Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd

Video

Podcasts

Individualized PsA Treatment With an IL-23i or a JAKi
Nov 02, 2026
DERM on RheumNow PODCAST (October 2026)
Oct 31, 2026
Mixed Drinks, Mixed Results (10.30.2026)
Oct 30, 2026
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Oct 28, 2026

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact

Nov 01, 2026

In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions

Read Post